Company intelligence / Profile preview

Adela

California, United Statesadelabio.com ↗

Ownership: Private
Development stage: Commercial

Overview

Adela has developed a patented cfMeDIP-seq platform for highly sensitive and specific capture of biologically relevant methylation signals from cell-free DNA. The technology enables early cancer detection, minimal residual disease assessment, and therapy response monitoring via blood tests. The first clinical product will be a tissue/tumor sample–agnostic MRD test. Current offerings are available as research-use-only assays to biopharma partners.

Therapeutic areas: Oncology
Modalities: Diagnostic testResearch assay
Industry: Molecular Diagnostics

Partnerships

Biopharmaceutical companies using the RUO assay for drug discovery/development partnerships; specifics not disclosed publicly.

Beyond the preview

Go deeper on Adela.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adela.

Explore the full profile